Tags

Type your tag names separated by a space and hit enter

Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.
Mov Disord. 2013 Jun; 28(6):836-9.MD

Abstract

BACKGROUND

Oxidative stress is involved in the progression of Parkinson's disease (PD). Recent studies have confirmed that molecular hydrogen (H₂) functions as a highly effective antioxidant in cultured cells and animal models. Drinking H₂-dissolved water (H₂-water) reduced oxidative stress and improved Parkinson's features in model animals.

METHODS

In this a placebo-controlled, randomized, double-blind, parallel-group clinical pilot study, the authors assessed the efficacy of H₂ -water in Japanese patients with levodopa-medicated PD. Participants drank 1,000 mL/day of H₂-water or pseudo water for 48 weeks.

RESULTS

Total Unified Parkinson's Disease Rating Scale (UPDRS) scores in the H₂-water group (n=9) improved (median, -1.0; mean ± standard deviation, -5.7 ± 8.4), whereas UPDRS scores in the placebo group (n=8) worsened (median, 4.5; mean ± standard deviation, 4.1 ± 9.2). Despite the minimal number of patients and the short duration of the trial, the difference was significant (P<0.05).

CONCLUSIONS

The results indicated that drinking H₂-water was safe and well tolerated, and a significant improvement in total UPDRS scores for patients in the H₂-water group was demonstrated.

Authors+Show Affiliations

Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

23400965

Citation

Yoritaka, Asako, et al. "Pilot Study of H₂ Therapy in Parkinson's Disease: a Randomized Double-blind Placebo-controlled Trial." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 28, no. 6, 2013, pp. 836-9.
Yoritaka A, Takanashi M, Hirayama M, et al. Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial. Mov Disord. 2013;28(6):836-9.
Yoritaka, A., Takanashi, M., Hirayama, M., Nakahara, T., Ohta, S., & Hattori, N. (2013). Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial. Movement Disorders : Official Journal of the Movement Disorder Society, 28(6), 836-9. https://doi.org/10.1002/mds.25375
Yoritaka A, et al. Pilot Study of H₂ Therapy in Parkinson's Disease: a Randomized Double-blind Placebo-controlled Trial. Mov Disord. 2013;28(6):836-9. PubMed PMID: 23400965.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial. AU - Yoritaka,Asako, AU - Takanashi,Masashi, AU - Hirayama,Masaaki, AU - Nakahara,Toshiki, AU - Ohta,Shigeo, AU - Hattori,Nobutaka, Y1 - 2013/02/11/ PY - 2012/11/08/received PY - 2012/12/21/revised PY - 2012/12/26/accepted PY - 2013/2/13/entrez PY - 2013/2/13/pubmed PY - 2014/1/31/medline SP - 836 EP - 9 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 28 IS - 6 N2 - BACKGROUND: Oxidative stress is involved in the progression of Parkinson's disease (PD). Recent studies have confirmed that molecular hydrogen (H₂) functions as a highly effective antioxidant in cultured cells and animal models. Drinking H₂-dissolved water (H₂-water) reduced oxidative stress and improved Parkinson's features in model animals. METHODS: In this a placebo-controlled, randomized, double-blind, parallel-group clinical pilot study, the authors assessed the efficacy of H₂ -water in Japanese patients with levodopa-medicated PD. Participants drank 1,000 mL/day of H₂-water or pseudo water for 48 weeks. RESULTS: Total Unified Parkinson's Disease Rating Scale (UPDRS) scores in the H₂-water group (n=9) improved (median, -1.0; mean ± standard deviation, -5.7 ± 8.4), whereas UPDRS scores in the placebo group (n=8) worsened (median, 4.5; mean ± standard deviation, 4.1 ± 9.2). Despite the minimal number of patients and the short duration of the trial, the difference was significant (P<0.05). CONCLUSIONS: The results indicated that drinking H₂-water was safe and well tolerated, and a significant improvement in total UPDRS scores for patients in the H₂-water group was demonstrated. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/23400965/Pilot_study_of_H₂_therapy_in_Parkinson's_disease:_a_randomized_double_blind_placebo_controlled_trial_ L2 - https://doi.org/10.1002/mds.25375 DB - PRIME DP - Unbound Medicine ER -